Email Updates

You are here

Home

HIV PrEP Priming of Immune Effectors (PREPPIE)

Status
Planned
Phase
Open Label
Principal Investigator(s)
Pietro Pala, MD
Objective

Can HIV-specific immunity develop in HIV uninfected humans exposed to HIV whilst receiving antiretroviral pre-exposure prophylaxis (PrEP)? Investigators will investigate this possibility in commercial sex workers in Kampala who will be receiving Truvada PrEP for one year.

Prevention Option(s)
PrEP
Study Design
Open label
Arms and Assigned Interventions
Description
All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
Mode of Delivery
Tablet
Products
TDF/FTC (Truvada)
ARMs
Experimental
Official Code
NCT02593409
Trial Sponsors
MRC/UVRI Uganda Research Unit on Aids
January 2016
June 2018
Enrollment
220
18
Years
Population
Women
Sites

MRC/UVRI Uganda Research Unit on AIDS

Masaka
Uganda